Myriad Genetics Stock Analysis
On average, wall street analysts predict that. According to the last reported balance sheet, myriad genetics had liabilities of us$271.0m due within 12 months, and liabilities of us$186.9m due beyond 12 months.
The company offers myrisk hereditary cancer, a dna sequencing test for hereditary cancers;
Myriad genetics stock analysis. Exclusive research and insights from bulls and bears. Myriad genetics stock is tanking after earnings. Buy or sell myriad genetics stock?
In recent trading, shares of myriad genetics, inc. 6, 2020 at 6:36 a.m. Get the latest myriad genetics stock price and detailed information including mygn news, historical charts and realtime prices.
Myriad genetics's share price could stay at $30.00 by nov 3, 2022. Myriad genetics, inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the united states and internationally. Myriad genetics inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart.
Book strategy guru based on strategy description score. Since then, mygn stock has increased by 123.0% and is now trading at $31.28. Find the latest myriad genetics, inc.
Myriad genetics stock price target cut to $14 from $17 at j.p. As for revenue growth, invitae is quickly catching up to myriad which hasn’t been able to grow revenues for ten quarters in a row now. Over the last year, myriad genetics, inc.’s stock price has increased by 46.13%.
Is currently approximately $ 26.61 per share. Technical analysis of myriad genetics inc. That tiny $240 million company now has a market cap of $4.5 billion compared to myriad genetics with a $2.5 billion market cap.
The stock has a consensus analyst rating of hold. a hold rating indicates that analysts believe investors should keep any existing positions they have in mygn, but not buy more shares or sell existing shares. Myriad genetics, inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the united states and internationally. Myriad genetics last announced its earnings results on november 9th, 2020.
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. The firm had revenue of $145.20 million for the quarter, compared to analyst estimates of $134.59 million. With 77,476,578 shares available for purchase and an average trading volume over the past 10 trading days of 531,190, it would take at least 8.026 days for all of the short holders to cover their shorts.
Wall street stock market & finance report, prediction for the future: The average myriad genetics stock price prediction forecasts a potential downside of n/a from the current mygn share price of $27.51. Is myriad genetics stock on sale?
Myriad genetics currently has 1 sell rating and 2 hold ratings from wall street analysts. () stock market info recommendations: You'll find the myriad genetics share forecasts, stock quote and buy / sell signals below.according to present data myriad genetics's mygn shares and potentially its market environment have been in a bullish cycle in the last 12.
(mygn) guru analysis based on 12/3/2021 close price. Get the top ten rated stocks using any of our guru models. Scores above 90% typically indicate strong interest.
Real time myriad genetics (mygn) stock price quote, stock graph, news & analysis. Bracanalysis, a dna sequencing test to assess the risk of developing breast and. As of the latest analysis, there are 4,263,582 shares shorted.
View the latest ratings for mygn. (mygn) stock analysis from seeking alpha’s top analysts: Investorsobserver gives myriad genetics inc (mygn) an overall rank of 43, which is below average.
A rank of 43 means that 57% of stocks. That was a remarkable call mr. Stock quote, stock chart, quotes, analysis, advice, financials and news for share myriad genetics, inc.
The reported ($0.15) earnings per share (eps) for the quarter, beating the consensus estimate of ($0.30) by $0.15.
Post a Comment for "Myriad Genetics Stock Analysis"